Fortress Biotech, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value
Fortress Biotech, Inc. (FBIO) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value of $11.72 million as of 2020-09-30, per its 10-Q filed 2020-11-09.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue · last filed 2020-11-09
- 2020-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $11.72M.
- 2020-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $11.56M.
- 2020-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $11.22M.
- 2019-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $11.18M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value as first filed |
|---|---|---|
| 2020-09-30 | $11.72M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $11.56M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $11.22M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $11.18M 10-Q · filed 2020-11-09 | |
| 2019-09-30 | $11.19M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $11.19M 10-Q · filed 2019-08-09 | |
| 2018-12-31 | $10.90M 10-K · filed 2020-03-16 | |
| 2018-09-30 | $10.66M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $11.14M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $20.67M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $21.83M 10-K · filed 2020-03-16 | |
| 2017-09-30 | $24.73M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $13.86M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $16.03M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $20.94M 10-K · filed 2019-03-18 | $20.94M 10-K · filed 2017-03-16 |
| 2016-09-30 | $6.84M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $2.07M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $1.57M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $2.60M 10-K · filed 2018-03-16 | $2.48M 10-K · filed 2016-03-15 |
| 2015-09-30 | $4.09M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $5.57M 10-Q · filed 2016-08-09 | |
| 2015-03-31 | $3.94M 10-Q · filed 2016-05-10 | |
| 2014-12-31 | $4.16M 10-K · filed 2017-03-16 | |
| 2013-12-31 | $0.00 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |